Lol... as i have said on many forums.. would not bother posting...

First 117 Last

Share
Profile

Follow
stardestr0yer

5,909 Posts.

88

05/07/18

19:47

Post #: 34171191
Share

Originally posted by Gwaihir ↑

On a more positive note for you guys, we got through the LiveWire Markets Bell Potter (John Hester) analysis for 2019 today, and the list of Bell Potter's most attractive stocks to invest in going forward - and guess who is there - yes, Elixinol. Target Price of $2.15

I personally think the fair value of the stock currently is around 70 cents, but what do I know, because I've been wrong many times.

But on a more personal note, I'd just like to see this stuff legalised in Australia, so that lives can be saved.

Anyway, here is the Bell Potter analysis.

Elixinol (EXL)

Elixinol is an established, leading brand in the nascent US market for hemp based nutraceutical products. The category is currently experiencing explosive revenue growth following recent regulatory changes to legalise the growing of hemp in the US and a growing acceptance of the clinical benefit from these products in controlling the symptoms of numerous chronic medical conditions.

The Australian operations of the group include Hemp Foods Australia (HFA) being a company focussed on the development of the market for Hemp Foods. This category is also expected to grow rapidly from a zero base. The catalyst for the sector was the inclusion of hemp foods on the Foods Standards Code.

The Group is led by Chief Executive Paul Benhaim who is the co-founder of both Elixinol US and Health Foods Australia. Following the IPO he retains 53% of the listed entity and is the largest shareholder by a considerable margin. Mr Benhaim is considered an expert in the field of industrial hemp and medicinal cannabis following more than two decades of experience in the sector both in Australia, the US and Europe.

The company has not provided earnings guidance for FY18, however, 1Q18 revenues grew by 24% over the prior sequential quarter. We expect further double digit growth for at least the remainder of the year and for some period thereafter.

We believe the imminent approval of the first medicinal cannabis product by the FDA in the US will provide further validation of the efficacy of CBD based medicines. Epidiolex is owned by GW Pharma and used for the treatment of Epilepsy in children. In our view this event is likely to have a flow on effect for other market participants including for the over the counter hemp CBD products markets by Elixinol US.

Our target price of $2.16 represents an upside of 56% to the current share price.

Speculative, Buy (Bell Potter)

Gw

Expand

Lol... as i have said on many forums.. would not bother posting brokers targets for companies that they floated... seen this so many times, but when the share price sinks... do you think they bother putting their hand in the pocket to support it given:
1. They usually get a minimum of 6% fee of what they raised
2. It is so UNDERVALUED to what their target is

Just my 2 cents

EXL Price at posting: $1.48 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Watchdog takes Webjet to court over alleged 'false' flight prices with hidden fees

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

PME

Pro Medicus signs landmark $330M deal to roll out imaging platform in US hospitals

OCN

Southern Cross Gold zooms in on 9 new high-grade zones above 20g/t at Golden Dyke

MTM

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

Chaos reigns markets – so let's take stock of where we're at ahead of December

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

SHN

Chimeric clocks $4.17M R&D tax rebate from Canberra

There are more pages in this discussion • 14 more messages in this thread...

First 117 Last

Add EXL (ASX) to my watchlist

(20min delay)
Last 0.4¢		Change -0.002(33.3%)		Mkt cap ! $6.605M

Open	High	Low	Value	Volume
0.4¢	0.5¢	0.4¢	$2.103K	475.4K

Buyers (Bids)

No.	Vol.	Price($)
17	7670493	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	924824	4

View Market Depth

No.	Vol.	Price($)
2	3797	4.490
1	8000	4.480
2	6000	4.470
1	358	4.460
3	3424	4.450

Price($)	Vol.	No.
4.500	31	1
4.510	342	1
4.520	397	1
4.530	370	1
4.540	825	2

Last trade - 14.04pm 29/11/2024 (20 minute delay)

EXL (ASX) Chart

Lol... as i have said on many forums.. would not bother posting...

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Watchdog takes Webjet to court over alleged 'false' flight prices with hidden fees

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Pro Medicus signs landmark $330M deal to roll out imaging platform in US hospitals

Southern Cross Gold zooms in on 9 new high-grade zones above 20g/t at Golden Dyke

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

Chaos reigns markets – so let's take stock of where we're at ahead of December

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Chimeric clocks $4.17M R&D tax rebate from Canberra

Buyers (Bids)

Sellers (Offers)